Table 3 Predictors of uncontrolled asthma in medium- and high-dose ICS/LABA cohorts.
Predictors of uncontrolled asthma | Medium-dose ICS/LABA cohort (N = 24,937) | High-dose ICS/LABA cohort (N = 8661) | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Sex | ||||
Female versus male | 1.131 (1.073, 1.193) | <0.0001 | 1.232 (1.122, 1.353) | <0.0001 |
Index year | ||||
2011 versus 2010 | 0.958 (0.867, 1.057) | 0.3918 | 1.004 (0.830, 1.216) | 0.9640 |
2012 versus 2010 | 0.790 (0.716, 0.872) | <0.0001 | 0.697 (0.573, 0.848) | 0.0003 |
2013 versus 2010 | 0.754 (0.682, 0.834) | <0.0001 | 0.616 (0.508, 0.747) | <0.0001 |
2014 versus 2010 | 0.819 (0.744, 0.902) | <0.0001 | 0.638 (0.534, 0.762) | <0.0001 |
2015 versus 2010 | 0.750 (0.625, 0.901) | 0.0020 | 0.449 (0.342, 0.591) | <0.0001 |
Asthma drugs (yes versus no) | ||||
SABA | 1.076 (1.005, 1.153) | 0.0368 | 1.176 (1.055, 1.311) | 0.0034 |
Maintenance systemic corticosteroids | 4.705 (3.769, 5.873) | <0.0001 | 3.429 (2.411, 4.877) | <0.0001 |
Number of asthma exacerbations 1-year pre-index (≥1 versus 0) | 1.666 (1.546, 1.796) | <0.0001 | 1.790 (1.592, 2.013) | <0.0001 |
Concomitant medications (yes versus no) | ||||
NSAIDs | 1.101 (1.034, 1.173) | 0.0027 | NA | |
Comorbidities (yes versus no) | ||||
Atrial fibrillation or other cardiac arrhythmias | 1.160 (1.051, 1.282) | 0.0033 | NA | |
Anaphylaxis | 1.617 (1.179, 2.218) | 0.0029 | NA | |
Eczema | 1.072 (1.016, 1.132) | 0.0115 | NA | |
GERD | 1.179 (1.098, 1.266) | <0.0001 | NA | |
Heart failure | 1.157 (1.030, 1.301) | 0.0142 | NA | |
Rhinitis/rhinosinusitis | 0.996 (0.881, 1.126) | 0.9521 | NA | |
Charlson Comorbidity Index groups | ||||
≥2 versus ≤1 | 1.049 (0.992, 1.109) | 0.0951 | NA | |
